Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

doi:10.1158/1078-0432.CCR-24-0400

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2024

Nguyen Charles B, Reimers Melissa A, Perera Chamila, Abida Wassim, Chou Jonathan, Feng Felix Y, Antonarakis Emmanuel S, McKay Rana R, Pachynski Russell K, Zhang Jingsong, Reichert Zachery R, Palmbos Phillip L, Caram Megan E V, Vaishampayan Ulka N, Heath Elisabeth I, Hopkins Alexander C, Cieslik Marcin P, Wu Yi-Mi, Robinson Dan R, Baladandayuthapani Veerabhadran, Chinnaiyan Arul M, Alva Ajjai S

Abstract excerpt

PURPOSE: CDK12 inactivation in metastatic castration-resistant prostate cancer (mCRPC) may predict immunotherapy responses. This phase 2 trial evaluated the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with CDK12-altered mCRPC. PATIENTS AND METHODS: Eligible patients had mCRPC with deleterious CDK12 alterations and any prior therapies except ICI. Cohort A received ipilimumab (1 mg/kg) with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Ipilimumab

Share to Neoplasm Metastasis

Share to Nivolumab

Share to Progression-Free Survival

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 38787530
DOI: 10.1158/1078-0432.CCR-24-0400
PMCID: PMC11293970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.PMID 38787530Read ↗

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.Semantic proximity Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Characterizing CDK12-Mutated Prostate CancersSemantic proximity Read ↗

A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.Semantic proximity Read ↗

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsSemantic proximity Read ↗

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Semantic proximity Read ↗

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Quantitative MHC class-I/-II gene expression levels in <i>CDK12</i> mutated prostate cancer reveal intratumorally T cell adaptive immune response in tumorsSemantic proximity Read ↗

Immunotherapy for Prostate Cancer: Treatments for the "Lethal" Phenotype.Semantic proximity Read ↗

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.Semantic proximity Read ↗

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.Semantic proximity Read ↗

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.